ArticleScientific reports2025
TLR7/8 ligands R848 and imiquimod induce differentiation of bone marrow cells from patients with myelodysplastic syndrome towards mature neutrophils.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Overcoming Immune Therapy Resistance in Cancer Through Innate Immune Reprogramming.International journal of molecular sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Myelodysplastic syndromes (MDS) and acute myeloid leukaemia (AML) arise as a consequence of acquisition and progressive accumulation of genetic and epigenetic modifications by haematopoietic stem and progenitor cells (HSPC) which result in an impaired cell differentiation and the clonal expansion of myeloid progenitors leading to blast-cell accumulation in bone marrow (BM) and myelodysplasia. TLRs are expressed on HSPC and play a role in modulating haematopoiesis by instructing commitment to the myeloid lineage, and therefore may have potential therapeutic application. We have determined the in vitro effect of R848 (TLR7/TLR8 agonist) and Imiquimod (TLR7 agonist), on differentiation, apoptosis and cell viability in primary cultures of bone marrow samples from MDS (n = 6) and AML patients (n = 13). Differentiation was determined by a combined approach of conventional flow cytometry and t-SNE (t-distributed stochastic neighbour embedding) analysis based on the expression of cell markers (CD34, CD11b, CD13, CD117 and CD45). Cell viability and apoptosis were determined according to standard procedures. Statistical analyses were performed according to the two-tailed Student's t test for dual comparison (treated versus control samples). All major cell populations of the differentiation path from blasts towards neutrophils were found. Treatment with R848 or with Imiquimod did not induce significant changes in cell differentiation in AML samples. However, both R848 and, to a lesser extent, Imiquimod were able to induce differentiation of bone marrow cells from MDS patients from myelocytes to mature neutrophils in five out of six samples. Results also showed absence of toxic effects of both ligands on cells from MDS patients, as both apoptosis and cell viability were not altered by treatments. As for the differentiation assays, the effect of both ligands on apoptosis and cell viability in primary cultures from AML patients was not significant. Treatment with TLR7/8 ligands can revert the blockade of myeloid differentiation in most MDS samples and increase the amount of neutrophils, and therefore could represent a potential alternative treatment for MDS patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.